Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK3280 Renal Function and PK Study in Healthy Subjects
NCT03990688Phase 1Completed
- Sponsor
- Ark Biosciences
- Start
- Oct 2019
- Primary completion
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of AK3280 in idiopathic pulmonary fibrosis (IPF) (4 arms), sponsored by Ark Biosciences. Primary endpoints: Measured Glomerular Filtration Rate at Day 14 and Change from baseline mGFR at Day 14. Started Oct 2019; status: completed.
02
Drugs
AK3280
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT03990688.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03990688.